newsfilter
← Latest News
GlobeNewswire·

Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 Preparing for a planned